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ABSTRACT 
Background: The presence of single nucleotide polymorphisms (SNPs) in the RET 
(REarranged during Transfection) gene has been investigated with regard to their potential 
role in the development or progression of medullary thyroid cancer (MTC) or 
pheochromocytomas (PHEO) in patients with the multiple endocrine neoplasia type 2 
(MEN2) syndrome. The aim of this study was to evaluate the spectrum of RET variants in 
France between 2003 and 2013, and an evaluation of the impact of SNPs on the MEN2 A 
phenotype.  
Methods: In this retrospective cohort study RET variants were screened in 5109 index 
cases and RET pathogenic variants were screened in 2214 relatives. Exons 5, 8, 10, 11, 13, 
14, 15 and 16 were characterized by Sanger sequencing. RET Non-SNP pathogenic variants, 
RET variants with unknown functional significance (VUS), and four RET SNP variants, i.e. 
G691S (rs1799939), L769L (rs1800861), S836S (rs1800862), and S904S (rs1800863) were 
characterized and are reported in index cases. In silico analysis and classification following 
the recommendation of the ACMG (American College of Medical Genetics and Genomics) 
was performed for RET variants with unknown functional effects. Each patient’s age at the 
time of diagnosis, sex, and the endocrine neoplasias present at molecular diagnosis were 
recorded.  
Results: Twenty-six single non-SNP RET variants VUS in RET without any well-defined risk 
profiles were found in 33 patients. Nine of these were considered probably pathogenic, 11 
of uncertain significance, and 6 as probably benign. Three double pathogenic variants 
found in 3 patients were classified as pathogenic. A study of the entire cohort showed that 
patients carrying non-SNP pathogenic variants or VUS in RET together with PHEO were 
diagnosed earlier than the others. The presence of the G691S SNP, or a combination of 
SNPs, increased the risk of developing PHEO, but did not modify the date of the diagnosis. 
No association was found between SNPs and medullary thyroid cancer (MTC) or 
hyperparathyroidism (HPTH). 
 
Conclusions: Our finding propose a classification of 15 of the 26 non-SNP RET variants VUS 
in RET without any well-defined risk profiles and suggest that the G691S SNP, or a 
combination of SNPs, may be associated with the development of PHEO. 
INTRODUCTION 
The human gene RET (REarranged during Transfection) gene encodes the tyrosine 
kinase transmembrane receptor required for the normal development of cell types derived 
from the neural crest, e.g. the thyroid C cells or the adrenal chromaffin cells. Gain-of-
function variants lead to the activation of the RET receptor and to an abnormal 
proliferation of these cells, which are pathognomonic in patients with multiple endocrine 
neoplasia type 2 (MEN2).  The MEN2 syndrome includes two clinically distinct forms, 
MEN2A and MEN2B, associated with distinct mutations in the RET gene as summarized in 
the Revised American Thyroid Association (ATA) Guidelines for the Management of 
Medullary Thyroid Cancer (1). MEN2A includes medullary thyroid cancer (MTC) in 
combination or not with pheochromocytoma (PHEO) and hyperparathyroidism (HPTH). 
MEN2B is characterized by MTC, PHEO, ganglioneuromatosis, mucosal neuromas and a 
marfanoid habitus. 
Germline gain-of-function RET variants mostly occur in exons 5, 8, 10, 11, 13, 14, 15 
and 16. Various consortia as well as the ATA have defined the risk profiles of each variant 
for the risk and aggressivity of MTC, giving estimations of the penetrance of MEN, 
recommending the optimal age for prophylactic thyroidectomy, and suggesting that 
asymptomatic patients carrying a germline disease-causing RET variant should be screened 
for PHEO and HPTH (1, 2). Some RET variants have not been categorized because of 
insufficient data. More information about these cases will be needed to provide adequate 
genetic counseling to patients and families. In 2010, an extensive study of RET variants in 
exon 10 evaluated the risk profiles of these patients and estimated the penetrance of 
MEN2 (3). The results showed that 50% penetrance was achieved by age 36 for MTC and 
by age 68 for PHEO. Another study analyzed clinical risk profiles and outcomes for RET 
variants at codon 634.  The outcomes varied according to the amino acid substitution and 
C634R seemed to be associated with a more aggressive MEN2A phenotype (4). However, 
some of the conclusions concerning RET variants are controversial. A recent study focusing 
on the RET Y791F variant, classified as moderate risk by the ATA, reported no association 
between this variant and susceptibility to MTC (5). The authors found a frequency of 0.008 
in the tumor-free cohorts originating in Central Europe. They, and other authors, also 
 
reported subjects harboring RET Y791F without the MEN2 syndrome (5, 6). It is therefore 
important to collect more data about patients in order to update the classification of RET 
variants in MTC. 
The presence of single nucleotide polymorphisms (SNPs) in the RET gene has been 
investigated with regard to their potential role in the development or progression of MTC 
or PHEO in patients with the MEN2 syndrome. Four SNPs, i.e. G691S (rs1799939), L769L 
(rs1800861), S836S (rs1800862), and S904S (rs1800863), have been regularly studied in 
the context of MEN2.  For each SNP, the findings were contradictory. Some clinical studies 
found an increased prevalence of RET SNPs in MTC (7-11), whereas others did not (12-14). 
A meta-analytic study on G691S, combining results from 968 cases of MTC and 2115 
controls, found that female patients were at a higher risk of the disease than males (15). 
Other studies suggest a potential additive effect of these SNPs on the susceptibility to MTC 
or PHEO (8, 11). Taken together, these findings suggest that the consideration of the 
possible modifying role of these SNPs may contribute to better clinical and follow-up 
management. 
Here we describe the spectrum of RET variants observed in the French population 
over the last 10 years collected from a nationwide database. We propose a classification of 
32 genotypes that have not been classified by the ATA (16). Finally, we explore the effects 
of multiple RET SNPs on the MEN2A phenotype. 
Patients and methods 
Organization of RET gene analysis in France 
In France, genetic counseling and RET molecular analysis are recommended in the 
presence of MTC, isolated or in combination with PHEO and HPTH.  It is provided free of 
charge to patients and their next of kin by the French National Cancer Institute (INCa). This 
institute, created under the French Public Health Act of 2004, plays a pivotal role in the 
national coordination of actions aimed at fighting cancer. Through its coordinated 
programs, INCa has funded a total of 11 laboratories across the country to perform RET 
molecular analyses, constituting the nationwide TenGen network.  
Database 
TenGen, which is affiliated with the French Endocrine Society, has set up an 
exhaustive national database to collect clinical and genetic information about these 
patients. The database has been declared to the French National Commission for 
Computerized Data and Individual Freedom (CNIL) and is registered under N° 91513. The 
TenGen network has verified all the data included in the RET database from 2003 to 2013. 
This study is nationwide and all centers performing RET gene analysis have contributed to 
the RET database. 
Patients 
Over the ten-year period from 2003 to 2013, 5109 index cases and 2214 relatives 
underwent RET proto-oncogene analysis. Index cases were diagnosed with various 
combinations of endocrine neoplasias, i.e. MTC, associated or not with PHEO or HPTH. 
Each index case belonged to apparently unrelated families according to the genetic 
counseling and the family name.  Each laboratory was invited to anonymize and complete 
a form for each index case. The information collected included each patient’s age at the 
time of diagnosis, sex, the endocrine neoplasias present, and the RET genetic variants. For 
screened relatives only the presence or absence of the RET pathogenic variant was 
available. 
Molecular characterization 
The germline RET variants, including SNP, in exons 5, 8, 10, 11, 13, 14 and 16 were 
analyzed (Genbank reference NM_020975.4).  Genomic DNA was obtained from peripheral 
blood leucocytes and the genotyping was done using direct sequencing. 
We use “variant” as a neutral term, “pathogenic variant” for variants affecting RET 
function, and the term “polymorphism” or “SNP” for a variant found at a frequency above 
1% or higher in the general population. The RET SNPs studied included G691S (rs1799939), 
L769L (rs1800861), S836S (rs1800862), and S904S (rs1800863). For variants for which a 
functional effect was not well-defined and that were not listed in the ATA MTC guidelines 
(1, 2, 17), we used the term “variant of unknown significance” (VUS). The variants were 
also classified following the recommendation of the ACMG (16). In silico analysis was 
performed by three different in silico bioinformatics algorithms, i.e. the scale-invariant 
feature transform (SIFT), polymorphism phenotyping (PolyPhen-2) and the 
MutationTaster. The term “non-SNP RET variants” wasere used to group together 
“pathogenic variants” and “variants of unknown significance”.   
Ethics 
Informed consent for genetic analysis and the use of data was obtained from all 
patients or their legal guardians according to the French governmental regulations. 
Statistical analysis 
Ordinal or nominal variables were summarized in terms of the frequency of 
occurrence and percentage, or the mean (± sd) for continuous variables.  Baseline 
characteristics were compared using either the Chi Square test for qualitative variables or 
Student’s t-test for quantitative variables. Kaplan-Meier curves were used for estimating 
the age-related penetrance of MEN2A according to the presence of PHEO, and 
comparisons between curves were made with a log-rank test.  Statistical analyses were 
performed using SPSS version 15 (SPSS Inc., Chicago, IL, USA). 
RESULTS  
Non-SNP Pathogenic variants and VUS in RET  in France 
Over the 10-year period from 2003-2013, 7323 tests were carried out, of which 
5109 concerned index cases and 2214 were used for family studies (Table 1). The 
frequency of non-SNP pathogenic variants and VUS in RET was 10.1% in the index cases, 
i.e. 514 of the 5109 patients tested, and 39.1% in the next of kin, i.e. 867 carriers of RET
pathogenic variants found in 2214 patients studied. We collected genetic data in 480 of
the 514 index cases (94.2%) in which the 8 RET exons had been analyzed during the period
2003-2013. The mean age of the patients was 47.3 ± 17.7 years and 59.9% of the patients
were women. The clinical feature at the time of diagnosis was MEN2A in 448 patients
(93.3%), and MEN2B in 32 patients (6.7%).
Among the 480 index cases, 477 patients had missense single variants (Figure 1). Of 
the single variants found, 51.6% are located in the extra-cellular domain of the receptor, 
affecting the cysteine codons.  The most frequent variants were V804M (17.2%), C634R 
(11.0%), C634Y (9.5%), L790F (8.9%) and M918T (6.0%), whereas the other represented 
less than 5% (as shown in Supplemental Data 1).  
Three of the patients had three different double variants, i.e (V804M; R844L); 
(K603Q; L790F); (D631Y; Y791F). Each of the variants observed was classified as pathogenic 
by the ATA; however, the double variants were not classified. 
Clinical and oncological features of patients carrying ATA classified variants 
Following the 2015 ATA Clinical Guidelines for MTC (1), the variants of 444 patients 
(92.3%) were listed in the guidelines and these patients had a well defined risk profile. 
Among these, 268 patients in our study (55.7%), could be qualified as carrying a “moderate 
risk” (corresponding to a combination of the former class A and class B pathogenic variants 
included in the 2009 ATA clinical guidelines (2), 146 patients (30.4%) as being at “high risk” 
(former Class C pathogenic variants, that includes patients with the RET codon C634 and 
A883F pathogenic variants), and 30 patients (6.2%) at the “highest risk” (former Class D 
pathogenic variants that includes MEN2B and RET codon M918T) (Figure 1).   
Clinical and oncological features of patients carrying non ATA-classified variants 
Among the index cases, 36 patients (7.7%) had variants not classified by the ATA, 
including 28 patients with 21 different single missense variants, 5 patients with 5 different 
synonymous RET variants, and three patients with double missense variants. Thirty 
patients were diagnosed with MTC and/or PHEO after age 40, whereas 6 patients were 
diagnosed before age 40 (Table 2).   
Two of the 5 synonymous RET variants, i.e. C620C (c.1860C>T) and S699S 
(c.2097C>T) have never been reported either in the NCBI dbSNP or in the Exome 
Aggregation Consortium (ExAC) databank: All patients with these variants were diagnosed 
after age 40.  
Of the 21 RET single variants not listed in the ATA classification (Table 2), 5 have 
never been reported either in the NCBI dbSNP or in the ExAC databank. Three of the latter, 
i.e. C515F (c.1544G>T), C541R (c.1621T>C) and N783S (c.2348A>G), were qualified as
“damaging” by three different in silico bioinformatics algorithms. The patient who carried
the C541R mutation was diagnosed before the age of one year with a suspicion of MEN2B
and Hirschsprung’s disease. The parents were asymptomatic, and no genetic analysis was
performed for them. Unfortunately, we did not have access to additional clinical data on
the patient to confirm MEN2B or Hirschprung’s disease. The two other variants, V704F
(c.2110G>T) and F644V (c.1930T>G), were qualified as “benign” or “damaging” depending
on the bioinformatics tool used. The patient carrying the F644V substitution was
diagnosed with MTC at age 35, and the patient carrying the V704F variant was diagnosed
with HPTH at age 49.
 Of the 16 single variants not classified by the ATA listed in the NCBI dbSNP or the 
ExAC databank, according to the 3 algorithms used, four were qualified as “benign” (one of 
the patients was diagnosed at age 21), five were qualified as “damaging” or “possibly 
damaging”, and seven RET variants were qualified as being either “benign” or “damaging” 
according to the algorithm used (two of these patients were diagnosed before age 40) 
(Table 2). 
 
We used the criteria for classifying these 21 single RET variants with the consensus 
recommendation of the ACMG. Nine variants for 11 patients could be classified as 
probably pathogenic, six as probably benign, and the others as variants “of unknown 
significance” (VUS).  
Clinical and oncological features of patients carrying RET double pathogenic variants 
Each single variant found in these cases is already listed in the ATA MTC guidelines 
with a moderate risk of aggressive MTC but the risks for double mutations have not been 
reported. One patient with a concomitant V804M and R844L substitution was diagnosed 
with MTC at age 51, with a metastatic node. Her twin sister was diagnosed with MTC at 
the same age but without any metastatic nodes.  The two pathogenic variants were on the 
same allele. The patient with K603Q and L790F had MTC alone at age 60. No family study 
was available for this patient. A 31-year-old male patient, diagnosed with PHEO, harbored 
D631Y and Y791F. The two variants were in distinct alleles. His father, carrying D631Y, was 
diagnosed with metastatic bilateral PHEO at age 65. No information was available for his 
mother.  
The non-SNP variant spectrum of the RET codon in MEN2A is associated with PHEO and 
HPTH 
We collected complete clinical information at the time of molecular analysis for 366 
of the 448 MEN2A patients. Among these patients, 77.3% had MTC alone, 17.5% had MTC 
and PHEO, 3.3% had MTC and HPTH, and 1.9% had MTC, PHEO and HPTH.  
The frequency of patients for whom PHEO was the first appearing lesion was 19.4% 
(71 of the 366 MEN2A patients). All the variants were pathogenic and already listed in the 
ATA MTC guidelines, except for G548S and K666T. Sixty-one of the 71 patients with PHEO 
had predominantly variants in exons 10 or 11 and these mainly concerned cysteine 
residues for these exons, except for the K666T variant. The mean age at the time of 
molecular diagnosis of MEN2A was significantly different between patients with or without 
 
PHEO, respectively 41.8 ±13.0 and 48.7 ±16.3 years (p=0.001, Student’s t-test and 
p<0.0001, Log-rank test) (Figure 2).  
Codon 634, which was most frequently mutated, was found to be affected in 112 
patients among which 55 (49,1%) had PHEO. In this group of 112 patients, 43 had C634R 
(38,4%), 33 had C634Y (29,5%), 11 had C634W (9,8%), 11 had C634S (9,8%), 6 had C634G 
(5,4%), 6 had C634F (5,4%), and 2 had C634L (1,8%). The risk of PHEO was about 50% for 
each variant except for C634F, where it was lower at 17%. The mean age at the time of 
diagnosis did not significantly differ between patients, with or without PHEO, harboring a 
codon 634 pathogenic variant.  
HPTH was found in 19 of the 366 MEN2A patients (5.2%). All the mutations were 
pathogenic variants already listed in the ATA MTC guidelines except for V704F. Thirteen of 
these 19 (68%) patients with HPTH harbored pathogenic variants affecting cysteines in 
exons 10 or 11. The most frequent was C634R, found in 7 of 19 patients. The other variants 
were found in the transmembrane domain (S649L in one patient) or the intracellular 
domain (V704F in one patient, and V804M in four patients).  
RET polymorphic alleles 
Clinical and molecular data were analyzed according to four SNPs, i.e. G691S 
(rs1799939), L769L (rs1800861), S836S (rs1800862), and S904S (rs1800863), in 244 of 366 
MEN2A patients with clinical information. The frequency of RET SNPs was similar to that 
reported in the literature, i.e. G691S 24.3%, L769L 22.1%, S836S 8.4%, and S904S 19.9%. 
The presence of the G691S SNP was associated with a higher risk of developing 
PHEO (p=0.036) (Figure 3A). The same tendency was observed when in analyses of the two 
groups of the ATA classification « high risk » group (patient carrier of variant in 634 codon) 
and « moderate risk » group (patient carrier of variant other than 634), without reaching 
the significance threshold for both group (p=0.07). However, for the patient with PHEO, 
statistical testing was not able to detect a difference in age at the time of molecular 
analysis in groups with or without G691S (46.7 ± 1.5 years with G691S and 44.3 ± 1.0 years 
without, p = 0.8). We examined whether the G691S SNP would change the age at which 
 
PHEO might have been diagnosed according to the 3 ATA categories of pathogenic 
variants. No difference between the different risk levels was found. 
We also examined whether the presence of one, two, three or four RET SNPs might 
increase the risk of PHEO. The distribution of the number of polymorphisms was 
significantly different between the four groups of patients (p=0.04).  Patients with PHEO 
were found to have a higher SNP number (1.38 ± 1.06) than patients without PHEO (1.05 ± 
0.95) (Figure 3). 
DISCUSSION 
We report the rate of new cases carrying pathogenic variants or VUS in non-SNP 
RET per year and their distribution in the French population studied between 2003 and 
2013. As recommended by INCa and based on the literature, the exons bearing activating 
mutations (exons 5, 8, 10, 11, 13, 14, 15 and 16) were analyzed in all patients. In our 480 
index cases, we found 74 different pathogenic variants or VUS non-SNP. Codon 634 was 
the most frequently altered codon, as already described (18, 19). However, the frequency 
spectrum of these variants is not universal and there are differences among ethnic groups, 
presumably caused by founder effects. For instance, in Greece, the G533C variant, with a 
prevalence of 36.2%, appears to be characteristic of a specific ethnic group (20). This 
variant has rarely been found in other series (18, 19, 21, 22), and in our study the 
frequency amounts to only 0.6% of patients. We found 8.9% of the patients to be carriers 
of L790F, a pathogenic variant that seems to be present more often in Germany and 
Slovenia but rarely in other European countries (Supplemental Data 2) (22, 23). Our 
spectrum of RET variants is similar to that found in Germany, but quite different from that 
in Italy, Spain, or Greece (18-21).  
The accumulation of genotype-phenotype data over the last decade has made it 
possible to define risk profiles, to estimate the penetrance of MEN for index cases, and to 
recommend the optimal age for a prophylactic thyroidectomy or PHEO and HPTH 
screening in asymptomatic carriers of RET pathogenic variants (1, 2, 24).  
 
In our study, 92.3% of the patients carrying pathogenic RET variants received such 
recommendations. However, for 36 patients carrying RET variants not classified by the 
ATA, the data were not sufficient to support a recommendation. The majority of these 
patients had been diagnosed after age 30, but two patients had been diagnosed at the age 
of one year and 21 years.  The patient diagnosed at the age of one year had a C541R 
variant associated with a MEN2B-like phenotype and Hirschprung’s disease. Unfortunately, 
there is no current available clinical data to further confirm the clinical diagnosis. This 
variant concerns one of the extracellular cysteine residues.  The C541R variant is predicted 
to be deleterious by the three bioinformatics algorithms used. Based on the consensus 
recommendation of the ACMG for the characterization of variants, the substitution is 
considered as probably pathogenic. A nonsense change in codon 541 in patients with 
Hirschsprung’s disease has been described in the literature but there is no precedence of a 
codon 541 variant with an activating mutation (25). The functional impact of C541R awaits 
confirmation by further studies. The patient diagnosed at age 21 had a V648I variant. With 
functional tests, this variant is qualified as having a low oncogenic potential (26), and the 
three bioinformatics algorithms have predicted it to be a tolerable substitution. This 
variant has been reported in trans with C634R for a patient with MTC and bilateral PHEO 
but his two children with the V648I variant had no evidence for the presence of tumors 
(27). Considering all these arguments, we consider this variant to be probably benign. The 
M918T pathogenic variant is qualified as the most aggressive variant in the ATA 
classification. In our study, we found another type of substitution at codon 918, i.e. 
M918V. Although this variant was also predicted to be deleterious by the three 
bioinformatics algorithms used, functional testing showed that it has a low oncogenic 
potential (26). As reported in a recent study showing a moderate risk of MTC associated 
with the M918V variant, our patient was diagnosed with MTC only at age 56 (28). The 
M918T pathogenic substitution has been shown to modify the three-dimensional structure 
of the protein, creating new hydrogen bonds and stabilizing its close conformation (29, 
30). Our unpublished data show that valine, a small amino acid that does not create new 
hydrogen bonds, does not alter the conformation of the protein. Based on these 
arguments, we believe that this variant is probably pathogenic. In contrast to M918T, the 
M918V variant is associated with a moderate risk of aggressive MTC in our patient.  
 
Concerning the combined mutations, each variant was classified as moderate risk 
by the ATA. For the concomitant presence of V804M and R844L, or K603Q and L790F, 
there is  no clinical evidence that suggests a need for upgrading the risk from “moderate” 
to “high”. For the patient carrying D631Y and Y791F, the diagnosis of PHEO was made 
earlier than in his father who carried D631Y alone. However, in the absence of information 
about his mother, and because of the controversy about the pathogenicity of Y791F, there 
is insufficient data to support a change in risk category. 
Overall, we have classified nine variants as probably pathogenic and six as probably 
benign.  It is known that MTC occurs at a variable age and aggressivity depending on the 
specific pathogenic variant. The clinical follow-up of these patients and further phenotype-
genotype information will be required to specify the MTC risk profile. As recommended for 
the patients carrying pathogenic RET variants, serum calcitonin assays and ultrasound 
examinations can serve as an indicator for MTC in patients carrying variants not yet 
classified by the ATA (1, 31, 32) 
Our results show that the distribution of mutations was significantly different 
between patients with or without PHEO. Patients with PHEO had predominantly mutations 
in exons 10 or 11 and these concerned cysteine residues. These tumors are known to 
produce catecholamines, and about one-third of the tumors are bilateral at initial 
diagnosis. The more dramatic clinical behavior explains why the mean age of diagnosis is 
lower when PHEO is the first manifestation of MEN 2A. Thus, the ATA recommended that 
screening for PHEO should begin by age 11 for children carrying a 634 pathogenic variant 
and by age 16 in children with other pathogenic variants. 
The polymorphic RET alleles G691S (rs1799939), L769L (rs1800861), S836S 
(rs1800862), and S904S (rs1800863) have sometimes been considered as disease 
modifiers. The role that the RET G691S polymorphism plays in the susceptibility to MTC 
has been investigated and a meta-analysis based on 11 studies, combining 968 MTC cases 
and 2115 controls, confirms the involvement of this RET variant in MTC (15), but no 
involvement in risk of PHEO has been reported. In silico analysis has shown that the G691S 
SNP changes the phosphorylation pattern that may enhance signal transduction. 
16 
Moreover, two functional studies (33, 34) have demonstrated that two pathogenic 
variants (S891A and K666Q), qualified as “moderate” risks according to the ATA 
classification, display a higher oncogenic potential when they are associated with the 
G691S substitution. We investigated whether G691S modifies the age at diagnosis for 
patients carrying pathogenic variants with low oncogenic potential, but no modifier effect 
was found. However, we found that the G691S variant increases the risk of PHEO 
independently of the 634 RET pathogenic variant. According to some studies, G691S 
should be described as a risk modifier in MEN2. The additive effect of RET polymorphisms 
on sporadic MTC and PHEO has been investigated including multiple RET variants, i.e. 
G691S, L769L, S836S, and S904S (8, 11). The results showed that three or more 
polymorphic alleles were not associated with age at diagnosis or tumor size, but increased 
the risk of lymph node and distant metastases at diagnosis of sporadic MTC. In the case of 
PHEO, the presence of two RET variants was associated with increased susceptibility to 
PHEO and age-related penetrance. We found no link between the number of SNPs and the 
age at diagnosis of MTC, but the susceptibility for PHEO increased. Our study is 
retrospective and evaluated the potential role of the 4 RET SNPs found in the 8 analyzed 
exons. Our results suggest that RET G691S or a combination of SNPs may affect the 
development of PHEO in MEN2.  These results need to be confirmed by family screening to 
identify an intra-familial co-segregation of these SNPs with PHEO.  
The main limitations of our work may be related to the retrospective nature of the 
collection of data from multiple centers and the heterogeneity of the observation due to 
the varying method of patient management over the ten-year period of the study. 
Moreover, it is likely that subjects carrying mutations with a low transforming activity may 
not have been diagnosed if they had no family histories and had not yet developed MEN2. 
Finally, our results offer a more comprehensive vision of the distribution of RET 
variants in France and, to our knowledge, this is the first exhaustive study of RET screening 
over a 10-year span in France. We report the clinical description of 36 patients carrying 
non-ATA-classified RET variants, and classify them according to the recommendations of 
the ACMG. Our results suggest that RET SNPs such as G691S, or a combination of SNPs, 
may be associated with the development of PHEO. This finding may have significant 
 
implications in the management of patients, particularly for the diagnosis of PHEO in 
patients carrying the G691S SNP. With the advent of next-generation sequencing, 
comprehensive analysis of the RET exome or the entire locus may be extended to all 
patients with MEN2 so that phenotype-genotype correlations for rare or unknown variants 
could be usefully implemented for the management of patients.  
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Table 1: RET molecular analysis performed and patient carriers of RET germline non-SNP pathogenic variants or VUS found in France for index 
cases or screened relatives (2003-2013). 
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Total
2003-2013
Total Index Cases MEN2 (N) 894 454 386 383 449 492 429 390 378 385 469 5 109
Patient with RET variants (N) 66 42 40 47 55 43 43 56 24 42 56 514
% 7,4% 9,3% 10,4% 12,3% 12,2% 8,7% 10,0% 14,4% 6,3% 10,9% 11,9% 10,1%
screened relatives (N) 217 264 203 200 205 206 179 210 147 150 233 2 214
Screened relatives with RET variants (N) 87 106 81 83 51 86 57 77 75 63 101 867
% 40,1% 40,1% 40,0% 41,5% 24,9% 41,7% 31,8% 36,7% 51,0% 42,0% 43,3% 39,1%
Total Patient with RET variants (N) 153 148 121 130 106 129 100 133 99 105 157 1381
Report completed by the INCa each year for index cases and screened relatives
 th
is
 p
ro
of
.
 
Table 2: Rare RET VUS non-SNP variants non ATA-classified: clinical feature, population 
database report, in silico predictive algorithms and proposition of classification following 
ACMG  
Exon genotype Protein change N Patient
dbSNP/NCBI database 
(Number of report)
ExAC 
(frequency) SIFT Polyphen2
Mutation 
Taster
oncogenic
potential in vitro 
(references)
Age at 
diagnosis
Clinical 
phénotype References
Classification 
following ACMG
5 c.0884C>T T295M 1 not reported 8.765e-06 T T T 49 MTC VUS
5 c.1013C>T T338I 1 rs377767433 (3) 4.32e-05 T T T low or No (26) 42 ND 18-26-35 VUS
8 c.1529 C>T A510V 2 rs201745826 (5) 0.0003 T T T potential (36) 75 ND 36 VUS
69 MTC
8 c.1531G>A E511K 2 rs201553718 (8) 0.0002 T T D potential (36) 73 MTC 36 VUS
38 MTC
8 c.1544G>T C515F 1 not reported not reported D D D 49 MTC likely pathogenic
8 c.1591T>C C531R 2 rs377767390 (1) not reported D P D potential (36) 59 MTC 36 likely pathogenic
58 MTC
8 c.1621T>C C541R 1 not reported not reported D D D 0,12 MEN2B-
Hirsprung
likely pathogenic
8 c.1642G>A G548S 2 rs374461212 (3) 4.555e-05 T D D 53 MTC and PHEO VUS
53 MTC
11 c.1930T>G F644V 1 not reported not reported T T D 35 MTC VUS
11 c.1942G>A V648I 3 rs77711105 (6) 9.076e-05 T T T low or No (26) 65 MTC 26-27 Likely benign
68 MTC
21 MTC
11 c.1997A>C K666T 1 rs377767439 (2) 8.242e-06 D D D 41 MTC and Pheo likely pathogenic
11 c.1998delinsT
TCT
2 rs377767440 (1) 8.242e-06 T D D 35 ND 37 likely pathogenic
58 MTC likely pathogenic
11 c.1998 G>C K666N 1 rs146646971(5) not reported T D D 63 MTC 36 likely pathogenic
11 c.1998G>T K666N 1 rs146646971 (5) 2.473e-05 T D D potential (36) 59 MTC 36-44 likely pathogenic
11 c.2110G>T V704F 1 not reported not reported T D D 49 HPT VUS
13 c.2342A>G Q781R 1 rs377767416 (2) not reported D D D 73 MTC 38-39 VUS
13 C.2348A>G N783S 1 not reported not reported D D D 57 MTC 40 VUS
13 c.2371T>A Y791N 1 rs377767417 (3) 2.503e-05 D P D 58 MTC and CCH 41 VUS
15 c.2647G>A A883T 1 rs377767428 (1) not reported T D D 68 MTC 42 likely pathogenic
15 c.2657G>A R886Q 1 rs373594744  (1) 3.377e-05 T D D 84 ND VUS
16 c.2752A>G M918V 1 rs377767442  (1) not reported D D D low or No (26) 56 MTC 26-28 likely pathogenic
8 c.1539G>A A513A 1 rs761430718 (1) 8.271e-06 60 MTC Likely benign
10 c.1860C>T C620C
1 not reported not reported 70 MTC and PHEO Likely benign
11 c.2037C>T P679P 1 rs55862116 (9) 1.128e-03 45 MTC Likely benign
c.2052G>A P648P 1 rs145122337 (2) 2.718e-04 75 MTC Likely benign
c.2097C>T S699S 1 not reported not reported 62 MTC Likely benign
14;14 c.[ 2410G>A 
(;)c.2531G>T]
[V804M(;)R844L
]
1 51 MTC 43 Pathogenic
10;13 c.[1807 A>C 
(;) c.2370 
G>T]
[K603Q(;)L790F] 1 60 MTC Pathogenic
11;13 c.1891G>T(;)c
.2372A>T
[D631Y(;)Y791F] 1 31 MTC and PHEO Pathogenic
SINGLE VARIANTS (missense)
SINGLE VARIANTS (synonymous)
DOUBLE VARIANTS
T tolerated; D deleterious; P possibly damaging; ND not done; CCH C Cell Hyperplasia
FIGURE LEGENDS 
Figure 1 : Pathogenic variants or VUS in RET for index cases and screened relatives from 
2003 to 2013. Classification by risk groups following the 2015 ATA clinical Guidelines for 
MTC and proposition of classifying variants not found in the Guidelines following the 
consensus recommendation of the ACMG. 
Figure 2: Patients with MEN2A carrying RET germline pathogenic variants or VUS non-
SNP variants (N=366 Index cases). (A) Age at the time of MEN2A diagnosis according to 
the presence or absence of PHEO for 366 patients and for 112 patients with a RET 634 
variant. Student’s-t-test was used to compare mean of age. (B) Age-related penetrance of 
MEN2A according to the presence or absence of PHEO for 366 patients. Kaplan–Meier 
estimates for the proportion of MEN2 patients who developed PHEO. The log-rank test 
was used to compare curves. 
Figure 3 : Additive effect of RET polymorphisms on PHEO in patients with MEN2A (N=244 
index cases). (A) Distribution of each of the four studied SNPs, i.e. G691S (rs1799939), 
L769L (rs1800861), S836S (rs1800862), and S904S (rs1800863) and number of SNP per 
MEN2A patient according to the presence or absence of PHEO. (B) Proportion of MEN2A 
patients with zero, one, two, three or four SNPs according to the presence or absence of PHEO.  
Supplemental data 1: RET pathogenic variants or VUS found in France between 
2003 and   2013 in index cases. 
Exon N(%) type of changgenotype N(%) codon N(%) Protein change
ATA risk level 
(2015)
ATA risk level
(2009)
5 2 (0,4)
5 substitution c.0884C>T 1 (0,2) 295 1 (0,2) T295M Not classified
5 substitution c.1013C>T 1 (0,2) 338 1 (0,2) T338I Not classified
8 17 (3,5)
8 substitution c.1529 C>T 2 (0,4) 510 2 (0,4) A510V Not classified
8 substitution c.1531G>A 2 (0,4) 511 2 (0,4) E511K Not classified
8 substitution c.1543T>A 3 (0,6) 515 4 (0,8) C515S Moderate risk A
8 substitution c.1544G>T 1 (0,2) 515 C515F Not classified
8 substitution c.1591T>C 2 (0,4) 531 2 (0,4) C531R Not classified
8
dup
c.1594dupAGGAGTGTG
1 (0,2)
529-531
1 (0,2)
531/9 base pair 
duplication Moderate risk A
8 substitution c.1597G>T 3 (0,6) 533 3 (0,6) G533C Moderate risk A
8 substitution c.1621T>C 1 (0,2) 541 1 (0,2) C541R Not classified
8 substitution c.1642G>A 2 (0,4) 548 2 (0,4) G548S Not classified
10 78 (16,2)
10 substitution c.1807A>C 1 (0,2) 603 1 (0,2) K603E Moderate risk A
10 substitution c.1826G>A 3 (0,6) 609 5 (1,0) C609Y Moderate risk B
10 substitution c.1826G>T 1 (0,2) C609F Moderate risk B
10 substitution c.1827C>G 1 (0,2) C609W Moderate risk B
10 substitution c.1831T>G 2 (0,4) 611 12 (2,5) C611G Moderate risk B
10 substitution c.1832G>A 7 (1,5) C611Y Moderate risk B
10 substitution c.1833C>G 3 (0,6) C611W Moderate risk B
10 substitution c.1852T>A 12 (2,5) 618 29 (6,0) C618S Moderate risk B
10 substitution c.1852T>C 6 (1,2) C618R Moderate risk B
10 substitution c.1853G>A 1 (0,2) C618Y Moderate risk B
10 substitution c.1853G>C 8 (1,7) C618S Moderate risk B
10 substitution c.1853G>T 1 (0,2) C618F Moderate risk B
10 substitution c.1854C>G 1 (0,2) C618W Moderate risk B
10 substitution c.1858T>C 10 (2,1) 620 31 (6,4) C620R Moderate risk B
10 substitution c.1858T>G 5 (1,0) C620G Moderate risk B
10 substitution c.1859  G>A 8 (1,7) C620Y Moderate risk B
10 substitution c.1859G>C 1 (0,2) C620S Moderate risk B
10 substitution c.1859G>T 3 (0,6) C620F Moderate risk B
10 substitution c.1860C>G 4 (0,8) C620W Moderate risk B
11 158 (32,9)
11 substitution c.1888 T>C 1 (0,2) 630 1 (0,2) C630R Moderate risk B
11 substitution c.1900T>A 12 (2,5) 634 144 (29,9) C634S High risk C
11 substitution c.1900T>C 53 (11,0) C634R High risk C
11 substitution c.1900T>G 7 (1,5) C634G High risk C
11 delins c.1901_1902delGCinsTG 2 (0,4) C634L High risk B
11 substitution c.1901G>A 46 (9,5) C634Y High risk C
11 substitution c.1901G>C 3 (0,6) C634S High risk C
11 substitution c.1901G>T 9 (1,9) C634F High risk C
11 substitution c.1902C>G 12 (2,5) C634W High risk C
11 substitution c.1930T>G 1 (0,2) 644 1 (0,2) F644V Not classified
11 substitution c.1942G>A 3 (0,6) 648 3 (0,6) V648I Not classified
11 substitution c.1946C>t 2 (0,4) 649 2 (0,4) S649L Moderate risk A
11 substitution c.1996A>G 1 (0,2) 666 7 (1,5) K666E Moderate risk A
11 substitution c.1997A>C 1 (0,2) K666T Not classified
11 substitution c.1998 G>C 1 (0,2) K666N Not classified
11 delins c.1998delinsTTCT 2 (0,4) K666 Not classified
11 substitution c.1998G>T 1 (0,2) K666N Not classified
11 substitution c.2110G>T 1 (0,2) 704 1 (0,2) V704F Not classified
13 66 (13,7)
13 substitution c.2304G>C 10 (2,1) 768 14 (2,9) E768D Moderate risk A
13 substitution c.2304G>T 4 (0,8) E768D Moderate risk A
13 substitution c.2342A>G 1 (0,2) 781 1 (0,2) Q781R Not classified
13 substitution C.2350A>G 1 (0,2) 783 1 (0,2) N783S Not classified
13 substitution c.2370G>C 5 (1,0) 790 43 (8,9) L790F Moderate risk A
13 substitution c.2370G>T 38 (7,9) L790F Moderate risk A
13 substitution c.2371T>A 1 (0,2) 791 7 (1,5) Y791N Not classified
13 substitution c.2372A>T 6 (1,2) Y791F Moderate risk A
14 95 (19,8)
14 substitution c.2410G>A 83 (17,2) 804 95 (19,7) V804M Moderate risk A
14 substitution c.2410G>C 3 (0,6) V804L Moderate risk A
14 substitution c.2410G>T 9 (1,9) V804L Moderate risk A
15 24 (5,0)
15 substitution c.2647_2648delGCinsTT 2 (0,4) 883 3 (0,6) A883F High risk D
15 substitution c.2647G>A 1 (0,2) A883T Not classified
15 substitution c.2657G>A 1 (0,2) 886 1 (0,2) R886Q Not classified
15 substitution c.2670T>G 20 (4,1) 891 20 (4,1) S891A Moderate risk A
16 32 (6,7)
16 substitution c.2735G>C 1 (0,2) 912 1 (0,2) R912P Moderate risk A
16 substitution c.2752A>G 1 (0,2) 918 30 (6,2) M918V Not classified
16 substitution c.2753T>C 30 (6,0) M918T Highest risk D
Double 
variants 3 (0,8)
10;13 double c.[1807 A>C(;)c.2370 G>T] 1 (0,2) 603-790 1 (0,2) K603Q;L790F Not classified
11;13 double c.1891G>T(;)c.2372A>T 1 (0,2) 631-791 1 (0,2) D631Y;Y791F Not classified
14;14 double c.[ 2410G>A (;)c.2531G>T] 1 (0,2) 804-844 2 (0,4) V804M;R844L Not classified
synonymous 5 (1,0)
8 substitution c.1539G>A 1 (0,2) 513 1 (0,2) A513A Not classified
10 substitution c.1860C>T 1 (0,2) 620 1 (0,2) C620C Not classified
11 substitution c.2037C>T 1 (0,2) 679 1 (0,2) P679P Not classified
substitution c.2052G>A 1 (0,2) 684 2 (0,4) P684P Not classified
substitution c.2097C>T 1 (0,2) 699 1 (0,2) S699S Not classified
 
Supplemental data 2: Distribution of RET germline pathogenic non SNP variants in 
European families. The table is modified from the 2013 manuscript by Machens et al. (19) 
Variants non SNPs RET classify in ATA 
Italy 
(n=244
) (18) 
German 
(n=205) 
(19) 
Spain  
(n=25) 
(21) 
Greece 
(n=58) 
(20) 
France 
(n=48
0) 
532 duplication 1 (0.2)
C515S 1(0.4) 3 (0.6)
G533C  
21 
(36.2) 3 (0.6)
K603E 1 (0.2)
C609F=R=G=S=Y 6 (2.5) 1 (0.5) 1 (3.9) 5 (1.0)
C611R=G=F=S=W=Y 
1 (0.4) 6 (3) 
12 
(2.5) 
C618R=G=F=S=Y  
15 
(6.1) 11 (5) 
1 
(3.85) 4 (6.9) 29 (6) 
C620R=G=F=S=W=Y 
9 (3.7) 14 (7) 
1 
(3.85) 5 (8.6) 
31 
(6.4) 
C630R=F=S=Y 4 (1.6) 1 (0.5) 1 (0.2)
C634R=G=F=S=W=Y  
85 
(34.8) 73 (36) 
17 
(65.4) 
19 
(32.8) 
144 
(29.9) 
S649L  2 (0.4)
K666E 1 (0.2)
E768D  
9 (3.7) 2 (1) 1 (3.9) 1 (1.7) 
14 
(2.9) 
L790F  
8 (3.3) 26 (13) 
43 
(8.9) 
Y791F * 2 (0.8) 14 (7) 7 (1.5)
V804L  
3 (1.2) 19 (9) 3 (5.2) 
12 
(2.5) 
V804M  
49 
(20.2)
83 
(17.2) 
A883F  2 (0.4)
S891A  
23 
(9.4) 6 (3) 
1 
(3.85)  
20 
(4.1) 
R912P  1 (0.2)
M918T  
17 
(7.0) 32 (16) 3(11.5) 5 (8.6) 
30 
(6.0) 
non-SNP RET variants, non classified in ATA 
12 
(4.9) 
36 
(7.5) 
* Erlic et al (6), Toledo et al (5), and ARUP MEN 2 data base classified Y791F as a rare non-
pathogenic variant wherease ATA MTC guidelines in 2009 and 2015  considered this
variant as pathogenic variant.
